Altogether, increasing the tumor mutational burden by PARP1 inhibition and mitochondrial deregulation could add CML to the cancer types that could benefit from immunotherapy. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.